SMO and skin basal cell carcinoma: These include vismodegib, the first FDA-approved SMO inhibitor, licensed for the treatment of basal cell carcinoma (BCC), and LY2940680 (taladegib) which is being developed for the treatment of BCC, small cell lung carcinoma, and a range of other solid tumors, and is currently undergoing phase 2 investigational studies (Figure 2).